The functional mechanisms by which NUBPL activators exert their influence are diverse and rooted in the modulation of intracellular signal transduction pathways. Compounds that elevate intracellular cyclic AMP (cAMP) levels do so by either direct stimulation of adenylate cyclase or inhibition of phosphodiesterases, leading to enhanced activation of protein kinase A (PKA). PKA then phosphorylates various substrates, including NUBPL, thus promoting its functional activity. Similarly, agents that stimulate protein kinase C (PKC) also contribute to the phosphorylation cascade, culminating in the activation of NUBPL. Moreover, modulation of phosphatase activity results in a sustained phosphorylated state of proteins, which in the case of NUBPL, translates to increased activity due to inhibited dephosphorylation.
Additional layers of regulation are apparent through the impact of small molecules on metal ion homeostasis and acetylation status of proteins. The presence of metal ions such as zinc can stabilize protein conformations, thereby potentially enhancing the activity of metalloproteins like NUBPL. Moreover, compounds that influence the activity of sirtuins, a class of deacetylases, may enhance NUBPL activity by deacetylating specific lysine residues, leading to its functional activation. Other small molecules exert their effect by modulating broader signaling pathways, which can result in the upregulation and activation of NUBPL, thus integrating NUBPL activity into the wider network of cellular signaling and ensuring its role in the cellular processes it is involved in is sustained and enhanced.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
Beta-adrenergic agonist that stimulates adenylate cyclase activity, raising intracellular cAMP and subsequently activating NUBPL through phosphorylation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-selective phosphodiesterase inhibitor that prevents cAMP degradation, thereby sustaining NUBPL activation via phosphorylation. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
Cell-permeable cAMP analog that activates PKA, which then may phosphorylate and activate NUBPL. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C which can phosphorylate NUBPL, leading to its activation. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Inhibits protein phosphatases PP1 and PP2A, leading to increased phosphorylation and activation of NUBPL. | ||||||
Zinc | 7440-66-6 | sc-213177 | 100 g | $48.00 | ||
Stabilizes protein structure and function, potentially enhancing the activity of metalloproteins like NUBPL. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Activates sirtuins which may deacetylate lysine residues on NUBPL, enhancing its activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Phosphodiesterase-4 inhibitor, increasing cAMP levels and potentially leading to NUBPL activation through phosphorylation. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Modulates signaling pathways such as NF-kB, which may result in upregulation and activation of NUBPL. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
Activates AMPK, which can lead to downstream phosphorylation and activation of NUBPL. | ||||||